Regeneron Pharmaceuticals, Inc.
REGN
$589.48
-$8.68-1.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.39B | 808.70M | 917.70M | 1.34B | 1.43B |
| Total Depreciation and Amortization | 135.10M | 126.90M | 126.40M | 121.70M | 120.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -154.40M | -20.10M | 305.10M | -107.20M | -290.50M |
| Change in Net Operating Assets | -227.90M | 129.60M | -86.40M | -63.90M | -908.50M |
| Cash from Operations | 1.14B | 1.05B | 1.26B | 1.29B | 354.00M |
| Capital Expenditure | -219.00M | -229.30M | -199.60M | -241.90M | -180.50M |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 20.10M |
| Cash Acquisitions | -- | -- | -11.50M | 0.00 | -5.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -875.00M | 876.80M | 561.70M | -332.50M | -391.80M |
| Cash from Investing | -1.09B | 647.50M | 350.60M | -574.40M | -557.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 31.50M | 60.60M | 90.90M | 254.70M | 437.60M |
| Repurchase of Common Stock | -1.07B | -1.05B | -1.23B | -855.30M | -915.70M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -92.60M | -93.80M | -- | -- | -- |
| Other Financing Activities | 0.00 | -10.30M | 0.00 | -33.40M | -- |
| Cash from Financing | -1.13B | -1.09B | -1.14B | -634.00M | -478.10M |
| Foreign Exchange rate Adjustments | 400.00K | 600.00K | -700.00K | 800.00K | -300.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.08B | 604.00M | 477.20M | 83.60M | -681.60M |